Predict your next investment

Venture Capital
maxwellbiotech.com

See what CB Insights has to offer

Investments

11

Portfolio Exits

1

Funds

1

About Maxwell Biotech Venture Fund

Maxwell Biotech Venture Fund (MBVF) is the first Russian venture fund fully dedicated to investments in the life sciences sector. The fund has been created with the participation of the Russian Venture Company (RVC). MBVF relies on an experienced international team of managers and financial and industry experts and has offices in Moscow and Boston. To date, MBVF has invested in 9 companies: OncoMax (oncology), NeuroMax (neuroscience), MetaMax (oncology & metabolic diseases), Infectex (infectious diseases), CardioNova (cardiovascular diseases), Hepatera (hepatology), Osteros Biomedica (cancer induced bone diseases), Eleventa (inflammatory respiratory diseases) and Photonics (novel lasers for medicine and dentistry). Products in these companies originated either from Russian scientists or were licensed for commercialization in Russia from international biotech, pharmaceutical and medical device companies.

Maxwell Biotech Venture Fund Headquarter Location

Alexander House, office 329 1 Bolshaya Yakimanka street

Moscow, 119180,

Russian Federation

+7 (495) 411-6992

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Maxwell Biotech Venture Fund News

Maxwell Biotech Venture Fund’s Portfolio Company Hepatera Announces Start of Second Phase 2 Clinical Trial of Myrcludex B in Chronic Hepatitis B/D Infection

May 25, 2016

× MOSCOW, May 25, 2016 /PRNewswire/ -- Hepatera LLC and it`s development partner MYR GmbH today announced the initiation of MYR 203, a Phase 2b open label, randomized clinical trial to evaluate efficacy and safety of Myrcludex B in combination with pegylated interferon alpha versus pegylated interferon alpha in chronically HBV/HDV сo-infected patients. 60 subjects will be enrolled in 10 centers in Russia. (Logo: http://photos.prnewswire.com/prnh/20140213/668442-b ) "We plan to complete the recruitment by the end of 2016 and to have first results in Q3 2018," said Dr. Alexander Alexandrov, Medical Director MYR GmbH. "The primary objective of the study is improvement of the HDV RNA sustained virologic response rates, but we are certainly also looking if the combination of Myrcludex B with an immunomodulator can improve HBsAg loss rates and become a milestone on the way to the HBV cure. The results of this trial will be complementary to the ongoing Phase 2b trial of Myrcludex on top of tenofovir in chronic HBV/HDV infection. " "Whereas pegylated interferon alpha is a de-facto treatment standard for hepatitis delta, the unmet need remains huge," said Pietro Lampertico, MD, Professor at University of Milan and member of MYR`s Clinical Advisory Board. "Myrcludex B has shown synergistic effects in combination with interferon in the previous trial, so we look forward to see if this novel drug can improve treatment outcomes in this devastating disease. " About Myrcludex B  Myrcludex B is a first-in-class entry inhibitor for treatment of chronic hepatitis B and D infections. The drug inhibits the recently identified HBV receptor on the hepatocyte surface and prevents the infection of healthy cells and viral spreading within the liver. About Hepatera  Hepatera is a biotechnology company. The main activity of the company is development of safe and effective drugs for the treatment of liver diseases for the Russian market. About MYR GmbH  MYR GmbH is a biotechnology company focused on drugs for the treatment of chronic hepatitis B and D virus infections. The company is supported by investors Maxwell Biotech and High-Tech Gründerfonds. About Maxwell Biotech Venture Fund  MBVF is the first Russian venture fund fully dedicated to investments in the life sciences sector. The fund has been created with participation of the Russian Venture Company. MBVF portfolio companies have nine innovative clinical drug candidates in development. Contacts

Maxwell Biotech Venture Fund Investments

11 Investments

Maxwell Biotech Venture Fund has made 11 investments. Their latest investment was in MYR as part of their Series B on October 10, 2014.

CBI Logo

Maxwell Biotech Venture Fund Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/31/2014

Series B

MYR

$10M

No

1

10/31/2014

Series B

MYR Pharmaceuticals

$9.97M

No

1

9/7/2012

Seed VC

Eleventa

Yes

4/3/2012

Unattributed VC

Subscribe to see more

Subscribe to see more

0

4/3/2012

Series A

Subscribe to see more

Subscribe to see more

0

Date

10/31/2014

10/31/2014

9/7/2012

4/3/2012

4/3/2012

Round

Series B

Series B

Seed VC

Unattributed VC

Series A

Company

MYR

MYR Pharmaceuticals

Eleventa

Subscribe to see more

Subscribe to see more

Amount

$10M

$9.97M

New?

No

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

0

0

Maxwell Biotech Venture Fund Portfolio Exits

1 Portfolio Exit

Maxwell Biotech Venture Fund has 1 portfolio exit. Their latest portfolio exit was MYR Pharmaceuticals on December 10, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/10/2020

Acquired

$99M

6

Date

12/10/2020

Exit

Acquired

Companies

Valuation

$99M

Acquirer

Sources

6

Maxwell Biotech Venture Fund Fund History

1 Fund History

Maxwell Biotech Venture Fund has 1 fund, including Maxwell Biotech Venture Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/31/2012

Maxwell Biotech Venture Fund

Multi-Stage Venture Capital

Closed

$125.95M

1

Closing Date

12/31/2012

Fund

Maxwell Biotech Venture Fund

Fund Type

Multi-Stage Venture Capital

Status

Closed

Amount

$125.95M

Sources

1

Maxwell Biotech Venture Fund Team

3 Team Members

Maxwell Biotech Venture Fund has 3 team members, including current Managing Partner, Alexey V Eliseev.

Name

Work History

Title

Status

Alexey V Eliseev

Managing Partner

Current

Dmitry Popov

Managing Partner

Current

Chris Wiltshire

Managing Director

Former

Name

Alexey V Eliseev

Dmitry Popov

Chris Wiltshire

Work History

Title

Managing Partner

Managing Partner

Managing Director

Status

Current

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.